Immunic Inc. buy Quitte
Start price
05.04.19
/
50%
€11.76
Target price
04.11.21
€28.86
Performance (%)
-24.80%
End price
05.11.21
€8.85
Summary
This prediction ended on 05.11.21 with a price of €8.85. The prediction for Immunic Inc. disappointed with a performance of -24.80%. Quitte has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Immunic Inc. | 25.475% | 25.475% | -45.815% | -88.424% |
iShares Core DAX® | 1.454% | 0.904% | 16.592% | 16.557% |
iShares Nasdaq 100 | -0.913% | 3.463% | 36.062% | 50.205% |
iShares Nikkei 225® | 2.355% | 3.830% | 14.881% | 10.110% |
iShares S&P 500 | 0.283% | 2.639% | 29.599% | 44.509% |
Comments by Quitte for this prediction
In the thread aussichtsreich
Immunic up 26% after hours on encouraging IMU-838 data
Sep. 5, 2019 5:08 PM ET|About: Immunic, Inc. (IMUX)|By: Douglas W. House, SA News Editor
Thinly traded micro cap Immunic (NASDAQ:IMUX) is up 26% after hours on modest volume in apparent response to a pre-planned interim analysis of its Phase 2 CALDOSE-1 study evaluating IMU-838 in patients with moderate-to-severe ulcerative colitis. The data showed activity at the lowest dose (10 mg) and tolerability at the highest dose (45 mg). The trial will continue with all three dosing arms (30 mg is the other). The expansion of the potentially effective dose range will increase the target enrollment to ~240 from 195, expected to be completed in H2 2020. Topline data should be available in Q1 2021. The company says IMU-838 is an orally available, next-generation immune modulator that dampens the immune response by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH) that plays a key role in intracellular metabolism of activated immune cells.
In the thread Immunic Inc. diskutieren
Unternehmenszusammenschluss mit Immunic
www.globenewswire.com/news-release/2019/04/04/1797376/0/en/Vital-Therapies-Inc-Announces-Stockholder-Approval-of-Business-Combination-with-Immunic-AG.html
In the thread Trading Immunic Inc.
Die von Quitte gewählte maximale Laufzeit wurde überschritten